Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NeuroMetrix Inc NURO

Healthcare Medical Devices
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two... see more

Recent & Breaking News (NDAQ:NURO)

NeuroMetrix Reports Q3 2024 Business Highlights

GlobeNewswire November 5, 2024

NeuroMetrix Reiterates its Review of Strategic Alternatives

GlobeNewswire August 13, 2024

NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options

GlobeNewswire August 6, 2024

NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

GlobeNewswire July 31, 2024

NeuroMetrix Reports Q1 2024 Business Highlights

GlobeNewswire May 15, 2024

NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

GlobeNewswire April 19, 2024

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

GlobeNewswire March 14, 2024

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

GlobeNewswire March 13, 2024

Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired

Accesswire March 12, 2024

Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.

Accesswire March 4, 2024

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

GlobeNewswire February 22, 2024

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call

GlobeNewswire February 15, 2024

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

GlobeNewswire February 13, 2024

NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024

GlobeNewswire January 8, 2024

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

GlobeNewswire December 12, 2023

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

GlobeNewswire December 5, 2023

NeuroMetrix Announces One-for-Eight Reverse Stock Split

GlobeNewswire November 20, 2023

NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023

GlobeNewswire October 30, 2023

NeuroMetrix Reports Q3 2023 Business Highlights

GlobeNewswire October 26, 2023

NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call

GlobeNewswire October 23, 2023